Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Hepatitis B
Interventions
Not listed
Lead sponsor
Medical Procare PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Los Angeles, California • San Jose, California • Flushing, New York + 2 more
Conditions
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis B Virus Infection
Interventions
GIGA-2339, Placebo
Drug
Lead sponsor
GigaGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Chandler, Arizona • Huntington Beach, California • Lake Forest, California + 9 more
Conditions
Chronic Hepatitis B
Interventions
FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2 Interventional Results available

Lamivudine and Adefovir to Treat Chronic Hepatitis B

NCT00023309
Conditions
HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
Interventions
Lamivudine and adefovir, Adefovir alone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis B
Interventions
GSK3228836, PegIFN, NA therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Sacramento, California • Iowa City, Iowa • Detroit, Michigan + 1 more
Conditions
Chronic Hepatitis B
Interventions
GS-4774, GS-9620, Tenofovir disoproxil fumarate (TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 13 more
Conditions
Chronic Viral Hepatitis C, Monoclonal B-Cell Lymphocytosis
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Hepatitis B
Interventions
Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
CHRONIC HEPATITIS B
Interventions
CTH Chronic Hepatitis B
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, Delaware
Conditions
Chronic Hepatitis b
Interventions
AB-729, Peg-IFNα-2a
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Tucson, Arizona • San Diego, California + 3 more
Conditions
Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
Interventions
Lamivudine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Interventions
Multi-analyte Blood Test
Diagnostic Test
Lead sponsor
Helio Genomics
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Timeline
2019 – 2025
U.S. locations
7
States / cities
Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more
Conditions
Hepatitis B, Chronic Disease
Interventions
entecavir, adefovir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Torrance, California + 7 more
Conditions
Chronic HBV Infection
Interventions
GS-4774, OAV Regimen
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 13 more
Conditions
Chronic Hepatitis B
Interventions
Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA)
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years to 65 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more
Conditions
Chronic Hepatitis B
Interventions
telbivudine, adefovir dipivoxil
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
Atlanta, Georgia • Flushing, New York • Sterling, Virginia
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Conditions
Chronic Hepatitis B
Interventions
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 71 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Conditions
Hepatitis C
Interventions
Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV)
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more
Conditions
Chronic Hepatitis B
Interventions
telbivudine or lamivudine
Drug
Lead sponsor
Novartis
Industry
Eligibility
16 Years to 70 Years
Timeline
Started 2003
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • San Diego, California + 2 more
Conditions
Chronic Hepatitis B
Interventions
TAF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
22
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 19 more